Cassava Sciences | PTIE - Current Liabilities


Cassava Sciences reported $41.95M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Abbott USD 16.15B 1.66B Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Cassava Sciences USD 41.95M 1.79M Sep/2026
Eisai JPY 371.5B 22.14B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Geron USD 74.25M 3.92M Sep/2026
J&J USD 55.46B 562M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Novartis USD 32.52B 777M Sep/2026
Novavax USD 329.84M 729K Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026